Prurigo nodularis (PN) is a debilitating chronic disease characterized by intense itching and excoriated hyperkeratotic nodules distributed on the trunk and extremities, especially the extensor surfaces. The pathophysiology includes complex and not yet well-understood mechanisms involving inflammation and ...
Prurigo nodularis appears as thick, scaly, raised bumps on the skin that are very itchy and can be painful. Severe itch is characteristic of PN and leads to scratching, bleeding, and thickening of the nodules. The bumps can be anywhere on the body but are always within reach, with the ar...
Dupilumab treatment for prurigo nodularis and pruritis J Drugs Dermatol, 18 (2019), pp. 940-942 Google Scholar The R Foundation, 2021 The R Foundation The R Project for Statistical Computing https://www.r-project.org/ (2021) (accessed 1 December 2019) Google Scholar Thijs et al., 2017 J...
Dupilumab for pediatric prurigo nodularis: A case report Dupilumab should be considered as an off-label treatment for refractory prurigo nodularis in children.doi:10.1111/pde.14464Fachler, TahelFaitataziadou, ... MMPV Fachler - 《Pediatric Dermatology》 被引量: 0发表: 2021年 Prevalence, incidence...
Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the pathogenesis of prurigo nodularis. ... S Kwatra,S Kammerer - 《Medicom Conference Report Aad》 被引量: 0发表: 2023年 Recent advances in treatment of prurigo nodularis Prurigo nodularis is a ...
Prurigo nodularis (PN) is a barely-known disease that causes considerable impairment of quality of life for which very scarce treatment alternatives are available.1 Recently, biological drugs and small molecules have been used as off-label treatments. In this article, we report the case of PN tr...
635 - Dupilumab is efficacious in patients with prurigo nodularis regardless of baseline lesion severity: pooled results from two phase 3 trials (LIBERTY-P... Dupilumab treatment for 24 weeks improves itch and skin lesions in patients with PN regardless of lesion severity at baseline, with an ...
Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. Expert Rev Clin Pharmacol. 2021;14(1):67-77. doi:10.1080/17512433.2021.1852080Google ScholarCrossref 20. Parthasarathy V, Cravero K, Deng J, et al. Circulating plasma IL-13 and periostin are ...
chronic prurigo (CP), including prurigo nodularis (PN), pharmaceutical compositions for use in the treatment of pruritus in a subject having CP or PN, uses of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of pruritus in a subject having CP or PN...
Dupilumab as promising treatment for prurigo nodularis: current evidences. J Dermatolog Treat. 2021;15:1–6. doi:10.1080/09546634.2021.1886232 7. Xiao Y, Li W. A case of intractable pruritic plaque psoriasis with treated with tofacitinib. Chin J Dermatovenereol. 2021;35(12):1380–1383. 8. ...